Artificial intelligence analysis to explore synchronize exercise, cobalamin, and magnesium as new actors to therapeutic of migraine symptoms: a randomized, placebo-controlled trial

被引:9
|
作者
Matin, Hanie [1 ]
Taghian, Farzaneh [1 ]
Chitsaz, Ahmad [2 ]
机构
[1] Islamic Azad Univ, Dept Sports Physiol, Isfahan Khorasgan Branch, Esfahan, Iran
[2] Isfahan Univ Med Sci, Fac Med, Dept Neurol, Esfahan, Iran
关键词
Calcitonin gene-related peptides; High-intensity interval training; Vitamin B12; Magnesium; In silico; AEROBIC EXERCISE; SENSITIZATION; ACTIVATION; MECHANISMS; PEPTIDE; MODELS; PAIN;
D O I
10.1007/s10072-021-05843-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Migraine is recognized as a complex neurological disorder that has imposed a social burden. We assessed the signaling pathways and molecular mechanisms based on the in silico analysis and predicted drug candidates by the biomedicine approach. Moreover, we evaluated high-intensity interval training and vitamin B12 + magnesium on women's migraine attacks and inflammatory status. Methods This study computed differential gene expression in migraine syndrome and the dimension network parameters visualized by software. Moreover, we proposed the functional mechanism and binding energy of essential micronutrients on macromolecules based on drug discovery. In this clinical trial, 60 cases were randomized to four groups, including applied high-intensity interval training (HIIT), cases consumed supplementation vitamin B12 and magnesium (Supp), cases applied high-intensity interval training, and consumed supplementation (HIIT + Supp), and migraine cases for 2 months. Serum levels of calcitonin gene-related peptide (CGRP) were measured at baseline and at the end of the study. In addition, migraine disability assessment score (MIDAS), frequency, intensity, and duration were recorded before and during interventions. Results In silico study revealed the association between inflammation signaling pathways and pathogenesis of migraine attacks as a remarkable pathomechanism in this disorder. Furthermore, serum concentrations of CGRP were significantly declined in the HIIT + Supp compared with other groups. In addition, MIDAS, frequency, intensity, and duration were reduced in the HIIT + Supp group compared with the other groups. Conclusion We found that the synergistic effects of cobalamin and magnesium followed by regular exercise could silence the inflammation signaling pathway, and a combination of HIIT + Supp could ameliorate migraine pain.
引用
收藏
页码:4413 / 4424
页数:12
相关论文
共 50 条
  • [31] Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia
    Davidson, Michael
    Saoud, Jay
    Staner, Corinne
    Noel, Nadine
    Luthringer, Elisabeth
    Werner, Sandra
    Reilly, Joseph
    Schaffhauser, Jean-Yves
    Rabinowitz, Jonathan
    Weiser, Mark
    Luthringer, Remy
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (12): : 1195 - 1202
  • [32] EFFICACY AND SAFETY OF MIN-101: A NEW DRUG FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA. A 12-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Davidson, Michael
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 : S57 - S57
  • [33] Responder Rates to Atogepant in Patients With Episodic Migraine: A Post Hoc Analysis of Results From a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Dodick, David W.
    Ailani, Jessica
    Goadsby, Peter J.
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Li, Ye
    Szegedi, Armin
    [J]. CEPHALALGIA, 2019, 39 : 183 - 184
  • [34] Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Dodick, D. W.
    Ailani, J.
    Goadsby, P. J.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Li, Y.
    Szegedi, A.
    [J]. HEADACHE, 2019, 59 : 79 - 80
  • [35] Estetrol (E4), a Promising New Treatment for Menopausal Vasomotor Symptoms: Beneficial Lipid and Carbohydrate Metabolism in a Phase 3 Randomized, Double-blind, Placebo-Controlled Trial
    Utian, Wulf
    Taziaux, Melanie
    Black, Amanda
    Gaspard, Ulysse
    Lobo, Rogerio
    Foidart, Jean Michel
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1259 - 1259
  • [36] Efficacy and Safety of Estetrol (E4), a Promising New Treatment for Menopausal Vasomotor Symptoms: Results of Two Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
    Utian, Wulf
    Taziaux, Melanie
    Black, Amanda
    Gaspard, Ulysse
    Lobo, Rogiero A.
    Foidart, Jean-Michel
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1454 - 1454
  • [37] Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
    Yu, Shengyuan
    Guo, Aihong
    Wang, Zhen
    Liu, Jianguang
    Tan, Ge
    Yang, Qian
    Zhang, Mingjie
    Yibulaiyin, Hasiyeti
    Chen, Huisheng
    Zhang, Yongbo
    Croop, Robert
    Sun, Yanhui
    Liu, Yu
    Zhao, Qian
    Lu, Zhihong
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [38] NEW THERAPEUTIC APPROACH TO FRAGILE X SYNDROME BASED ON A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND PHASE II TRIAL TO TEST THE EFFECTIVENESS OF ASCORBIC ACID AND ALPHA-TOCOPHEROL
    Perez-Costillas, L.
    Calvo-Medina, R.
    Quintero, C.
    Heredia-Farfan, R.
    Sanchez-Salido, L.
    Lima-Cabello, E.
    Higuero-Tapiador, A.
    Arco-Herrera, I.
    Fernandez-Carvajal, I.
    Diego-Otero, Y.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 49 - 49
  • [39] Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial
    Beeh, Kai-Michael
    Beier, Jutta
    Candler, Henning
    Wittig, Thomas
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2877 - 2884
  • [40] Tocilizumab in patients with giant cell arteritis: analysis of new-onset and relapsing subgroups from a randomized, double-blind, placebo-controlled, phase 3 trial
    Birchwood, Christine
    Tuckwell, Katie
    Dimonaco, Sophie
    Klearman, Micki
    Collinson, Neil
    Stone, John H.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)